These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 24335203)
1. Pityriasis rosea in a hepatitis B-positive patient treated with pegylated interferon α2a: report of a case and review of the literature. Drago F; Javor S; Bruzzone L; Drago F; Parodi A; Picciotto A Dermatology; 2014; 228(1):10-3. PubMed ID: 24335203 [TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546 [TBL] [Abstract][Full Text] [Related]
4. Recurrence of hepatitis C virus infection during pityriasis rosea. Drago F; Javor S; Parodi A Acta Derm Venereol; 2013 Jul; 93(4):483. PubMed ID: 23165950 [No Abstract] [Full Text] [Related]
5. Persistent pityriasis rosea: an unusual form of pityriasis rosea with persistent active HHV-6 and HHV-7 infection. Drago F; Broccolo F; Ciccarese G; Rebora A; Parodi A Dermatology; 2015; 230(1):23-6. PubMed ID: 25612842 [TBL] [Abstract][Full Text] [Related]
6. Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection. Colvin RA; Tanwandee T; Piratvisuth T; Thongsawat S; Hui AJ; Zhang H; Ren H; Chen PJ; Chuang WL; Sobhonslidsuk A; Li R; Qi Y; Praestgaard J; Han Y; Xu J; Stein DS; J Gastroenterol Hepatol; 2015 Jan; 30(1):184-91. PubMed ID: 24995515 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience. Ratnam D; Dev A; Nguyen T; Sundararajan V; Harley H; Cheng W; Lee A; Rusli F; Chen R; Bell S; Pianko S; Sievert W J Gastroenterol Hepatol; 2012 Sep; 27(9):1447-53. PubMed ID: 22168789 [TBL] [Abstract][Full Text] [Related]
8. Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7. Broccolo F; Drago F; Careddu AM; Foglieni C; Turbino L; Cocuzza CE; Gelmetti C; Lusso P; Rebora AE; Malnati MS J Invest Dermatol; 2005 Jun; 124(6):1234-40. PubMed ID: 15955099 [TBL] [Abstract][Full Text] [Related]
9. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H; J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085 [TBL] [Abstract][Full Text] [Related]
10. Pityriasis Rosea after COVID-19 Infection. Prtajin M; Ljubojević Hadžavdić S Acta Dermatovenerol Croat; 2022 Dec; 30(4):265-266. PubMed ID: 36919396 [TBL] [Abstract][Full Text] [Related]
11. The role of human herpesvirus 6, human herpesvirus 7, Epstein-Barr virus and cytomegalovirus in the aetiology of pityriasis rosea. Canpolat Kirac B; Adisen E; Bozdayi G; Yucel A; Fidan I; Aksakal N; Gurer MA J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):16-21. PubMed ID: 18713231 [TBL] [Abstract][Full Text] [Related]
12. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation. Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110 [TBL] [Abstract][Full Text] [Related]
14. Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: A case report and literature review. Wang CS; Chen HH; Liu SH J Formos Med Assoc; 2022 May; 121(5):1003-1007. PubMed ID: 35012825 [TBL] [Abstract][Full Text] [Related]
15. Early administration of ultraviolet treatment is effective in pegylated interferon alpha-induced severe acute exacerbation of psoriasis: a case report and short review of the literature. Tekin NS; Ustundag Y; Tekin IO; Koca R; Altinyazar HC Int J Clin Pract; 2010 Jan; 64(1):101-3. PubMed ID: 20089020 [No Abstract] [Full Text] [Related]
16. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects? Gluhovschi C; Gadalean F; Kaycsa A; Curescu M; Sporea I; Gluhovschi G; Petrica L; Velciov S; Bozdog G; Bob F; Vernic C; Cioca D Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):744-50. PubMed ID: 21320001 [TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B. Piccolo P; Lenci I; di Paolo D; Demelia L; Sorbello O; Nosotti L; Angelico M Antivir Ther; 2013; 18(1):57-64. PubMed ID: 22872648 [TBL] [Abstract][Full Text] [Related]
18. Generalized flare of pustular psoriasis induced by PEGylated interferon-α2b therapy for chronic hepatitis C. Wu MC; Lee JY Australas J Dermatol; 2012 Nov; 53(4):e69-72. PubMed ID: 23157789 [TBL] [Abstract][Full Text] [Related]
19. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study. Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612 [TBL] [Abstract][Full Text] [Related]
20. Pegylated interferon alpha-2a-associated life-threatening Evans' syndrome in a patient with chronic hepatitis C. Lambotte O; Gelu-Simeon M; Maigne G; Kotb R; Buffet C; Delfraissy JF; Goujard C J Infect; 2005 Oct; 51(3):e113-5. PubMed ID: 16230187 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]